Transgenomic has entered an agreement with PerkinElmer to market and distribute its oncology diagnostic test portfolio of products.
PerkinElmer will have the nonexclusive right to begin sales, marketing, distribution, and field service activities in territories outside the U.S for Transgenomic’s line of molecular diagnostic oncology products, including CRC RAScan™ and ACE™ kits, for use on PerkinElmer’s LabChip® MultiDx platform. The collaboration will be effective at the start of next year and initially launch in Europe.
The CRC RAScan provides a single kit solution for detecting KRAS and NRAS genetic mutations that are relevant when considering administration of select EGFR inhibitor therapies associated with metastatic colorectal cancer, according to Transgenomic. The companies will offer testing solutions that include DNA extraction, oncology diagnostic assays, and high performance microfluidics instrumentation.
Last month, Transgenomic signed a seperate diagnostic test agreement with PDI to commercialize CardioPredict™, Transgenomic’s broad-based genetic assay, which the company said identifies a patient's specific genes that influence the effectiveness and safety of many commonly used cardiovascular drugs.